Table 1 Open in new tab Patient and...

	Phase II: RT + TMZ	Phase II: RT + Everolimus + TMZ	Total
Age, y
≤49	23	27.7	19	21.6	42	24.6
50–59	27	32.5	19	21.6	46	26.9
60–69	20	24.1	35	39.8	55	32.2
≥70	13	15.7	15	17.0	28	16.4
Sex
Male	46	55.4	56	63.6	102	59.6
Female	37	44.6	32	36.4	69	40.4
Race
Black or African American	4	4.8	0	0.0	4	2.3
Native Hawaiian or Other Pacific Islander	0	0.0	1	1.1	1	0.6
White	76	91.6	86	97.7	162	94.7
More than one race	2	2.4	0	0.0	2	1.2
Unknown or not reported	1	1.2	1	1.1	2	1.2
Ethnicity
Hispanic or Latino	2	2.4	5	5.7	7	4.1
Not Hispanic or Latino	77	92.8	78	88.6	155	90.6
Unknown (individuals not reporting ethnicity)	4	4.8	5	5.7	9	5.3
KPS
70–80	25	30.1	32	36.4	57	33.3
90–100	58	69.9	56	63.6	114	66.7
Surgery
Subtotal	34	41.0	42	47.7	76	44.4
Total (gross)	48	57.8	45	51.1	93	54.4
Other	1	1.2	1	1.1	2	1.2
Neurologic Function
No symptoms	26	31.3	32	36.4	58	33.9
Minor symptoms	45	54.2	40	45.5	85	49.7
Moderate symptoms	12	14.5	16	18.2	28	16.4
RPA class*
III	16	19.3	15	17.0	31	18.1
IV	57	68.7	61	69.3	118	69.0
V	10	12.0	12	13.6	22	12.9

	Phase II: RT + TMZ	Phase II: RT + Everolimus + TMZ	Total
Age, y
≤49	23	27.7	19	21.6	42	24.6
50–59	27	32.5	19	21.6	46	26.9
60–69	20	24.1	35	39.8	55	32.2
≥70	13	15.7	15	17.0	28	16.4
Sex
Male	46	55.4	56	63.6	102	59.6
Female	37	44.6	32	36.4	69	40.4
Race
Black or African American	4	4.8	0	0.0	4	2.3
Native Hawaiian or Other Pacific Islander	0	0.0	1	1.1	1	0.6
White	76	91.6	86	97.7	162	94.7
More than one race	2	2.4	0	0.0	2	1.2
Unknown or not reported	1	1.2	1	1.1	2	1.2
Ethnicity
Hispanic or Latino	2	2.4	5	5.7	7	4.1
Not Hispanic or Latino	77	92.8	78	88.6	155	90.6
Unknown (individuals not reporting ethnicity)	4	4.8	5	5.7	9	5.3
KPS
70–80	25	30.1	32	36.4	57	33.3
90–100	58	69.9	56	63.6	114	66.7
Surgery
Subtotal	34	41.0	42	47.7	76	44.4
Total (gross)	48	57.8	45	51.1	93	54.4
Other	1	1.2	1	1.1	2	1.2
Neurologic Function
No symptoms	26	31.3	32	36.4	58	33.9
Minor symptoms	45	54.2	40	45.5	85	49.7
Moderate symptoms	12	14.5	16	18.2	28	16.4
RPA class*
III	16	19.3	15	17.0	31	18.1
IV	57	68.7	61	69.3	118	69.0
V	10	12.0	12	13.6	22	12.9

Table 1

Patient and tumor characteristics for all eligible patients

	Phase II: RT + TMZ		Phase II: RT + Everolimus + TMZ		Total
Patient or Tumor Characteristic	n	%	n	%	n	%
Age, y
≤49	23	27.7	19	21.6	42	24.6
50–59	27	32.5	19	21.6	46	26.9
60–69	20	24.1	35	39.8	55	32.2
≥70	13	15.7	15	17.0	28	16.4
Sex
Male	46	55.4	56	63.6	102	59.6
Female	37	44.6	32	36.4	69	40.4
Race
Black or African American	4	4.8	0	0.0	4	2.3
Native Hawaiian or Other Pacific Islander	0	0.0	1	1.1	1	0.6
White	76	91.6	86	97.7	162	94.7
More than one race	2	2.4	0	0.0	2	1.2
Unknown or not reported	1	1.2	1	1.1	2	1.2
Ethnicity
Hispanic or Latino	2	2.4	5	5.7	7	4.1
Not Hispanic or Latino	77	92.8	78	88.6	155	90.6
Unknown (individuals not reporting ethnicity)	4	4.8	5	5.7	9	5.3
KPS
70–80	25	30.1	32	36.4	57	33.3
90–100	58	69.9	56	63.6	114	66.7
Surgery
Subtotal	34	41.0	42	47.7	76	44.4
Total (gross)	48	57.8	45	51.1	93	54.4
Other	1	1.2	1	1.1	2	1.2
Neurologic Function
No symptoms	26	31.3	32	36.4	58	33.9
Minor symptoms	45	54.2	40	45.5	85	49.7
Moderate symptoms	12	14.5	16	18.2	28	16.4
RPA class*
III	16	19.3	15	17.0	31	18.1
IV	57	68.7	61	69.3	118	69.0
V	10	12.0	12	13.6	22	12.9

	Phase II: RT + TMZ		Phase II: RT + Everolimus + TMZ		Total
Patient or Tumor Characteristic	n	%	n	%	n	%
Age, y
≤49	23	27.7	19	21.6	42	24.6
50–59	27	32.5	19	21.6	46	26.9
60–69	20	24.1	35	39.8	55	32.2
≥70	13	15.7	15	17.0	28	16.4
Sex
Male	46	55.4	56	63.6	102	59.6
Female	37	44.6	32	36.4	69	40.4
Race
Black or African American	4	4.8	0	0.0	4	2.3
Native Hawaiian or Other Pacific Islander	0	0.0	1	1.1	1	0.6
White	76	91.6	86	97.7	162	94.7
More than one race	2	2.4	0	0.0	2	1.2
Unknown or not reported	1	1.2	1	1.1	2	1.2
Ethnicity
Hispanic or Latino	2	2.4	5	5.7	7	4.1
Not Hispanic or Latino	77	92.8	78	88.6	155	90.6
Unknown (individuals not reporting ethnicity)	4	4.8	5	5.7	9	5.3
KPS
70–80	25	30.1	32	36.4	57	33.3
90–100	58	69.9	56	63.6	114	66.7
Surgery
Subtotal	34	41.0	42	47.7	76	44.4
Total (gross)	48	57.8	45	51.1	93	54.4
Other	1	1.2	1	1.1	2	1.2
Neurologic Function
No symptoms	26	31.3	32	36.4	58	33.9
Minor symptoms	45	54.2	40	45.5	85	49.7
Moderate symptoms	12	14.5	16	18.2	28	16.4
RPA class*
III	16	19.3	15	17.0	31	18.1
IV	57	68.7	61	69.3	118	69.0
V	10	12.0	12	13.6	22	12.9

RT = radiotherapy. *Stratification factor.